vs
Side-by-side financial comparison of Curbline Properties Corp. (CURB) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($60.1M vs $54.1M, roughly 1.1× Curbline Properties Corp.). Curbline Properties Corp. runs the higher net margin — 17.6% vs -92.6%, a 110.2% gap on every dollar of revenue.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
CURB vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $54.1M | $60.1M |
| Net Profit | $9.6M | $-55.6M |
| Gross Margin | — | 88.1% |
| Operating Margin | 17.8% | -87.1% |
| Net Margin | 17.6% | -92.6% |
| Revenue YoY | — | 83.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.08 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | $54.1M | $57.3M | ||
| Q3 25 | $48.6M | $51.3M | ||
| Q2 25 | $41.4M | $48.5M | ||
| Q1 25 | $38.7M | $32.7M | ||
| Q4 24 | — | $41.8M | ||
| Q3 24 | $29.8M | $33.3M | ||
| Q2 24 | — | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | $9.6M | $-47.5M | ||
| Q3 25 | $9.4M | $-52.9M | ||
| Q2 25 | $10.4M | $-46.6M | ||
| Q1 25 | $10.6M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $-15.4M | $-43.6M | ||
| Q2 24 | — | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | 17.8% | -82.2% | ||
| Q3 25 | 19.3% | -102.6% | ||
| Q2 25 | 25.3% | -93.4% | ||
| Q1 25 | 27.6% | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | -51.8% | -132.0% | ||
| Q2 24 | — | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | 17.6% | -83.0% | ||
| Q3 25 | 19.2% | -103.1% | ||
| Q2 25 | 25.1% | -96.1% | ||
| Q1 25 | 27.3% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | -51.8% | -131.2% | ||
| Q2 24 | — | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $0.08 | $-0.73 | ||
| Q3 25 | $0.09 | $-0.82 | ||
| Q2 25 | $0.10 | $-0.75 | ||
| Q1 25 | $0.10 | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | $-0.15 | $-0.73 | ||
| Q2 24 | — | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $289.6M | $340.6M |
| Total DebtLower is stronger | $423.2M | — |
| Stockholders' EquityBook value | $1.9B | $122.9M |
| Total Assets | $2.5B | $442.3M |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | $289.6M | $388.9M | ||
| Q3 25 | $430.1M | $416.1M | ||
| Q2 25 | $429.9M | $291.0M | ||
| Q1 25 | $594.0M | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | $2.5M | $298.4M | ||
| Q2 24 | — | $319.1M |
| Q1 26 | — | — | ||
| Q4 25 | $423.2M | — | ||
| Q3 25 | $396.4M | — | ||
| Q2 25 | $99.1M | — | ||
| Q1 25 | $99.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $122.9M | ||
| Q4 25 | $1.9B | $139.1M | ||
| Q3 25 | $1.9B | $148.8M | ||
| Q2 25 | $1.9B | $-11.9M | ||
| Q1 25 | $1.9B | $18.9M | ||
| Q4 24 | — | $21.7M | ||
| Q3 24 | $1.1B | $11.2M | ||
| Q2 24 | — | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | $2.5B | $480.2M | ||
| Q3 25 | $2.4B | $506.9M | ||
| Q2 25 | $2.1B | $372.7M | ||
| Q1 25 | $2.1B | $386.7M | ||
| Q4 24 | — | $392.3M | ||
| Q3 24 | $1.2B | $363.6M | ||
| Q2 24 | — | $381.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.21× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $124.6M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 13.04× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $124.6M | $-25.4M | ||
| Q3 25 | $39.2M | $-26.6M | ||
| Q2 25 | $34.2M | $-23.3M | ||
| Q1 25 | $25.4M | $-40.4M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | — | $-25.2M | ||
| Q2 24 | — | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | 13.04× | — | ||
| Q3 25 | 4.19× | — | ||
| Q2 25 | 3.28× | — | ||
| Q1 25 | 2.40× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
